Pembrolizumab monotherapy is demonstrated to significantly prolong overall survival (OS) compared to platinum-doublet chemotherapy as a first-line treatment in non-small cell lung cancer (NSCLC) patients with advanced or metastatic disease whose tumors have high PD-L1 immunohistochemistry expression (≥50%) in the absence of EGFR or ALK gene alterations [1]. Here, ALK is linked to non-small cell lung carcinoma.